739 related articles for article (PubMed ID: 35095862)
1. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
2. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
4. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
5. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.
Kwa S; Lai L; Gangadhara S; Siddiqui M; Pillai VB; Labranche C; Yu T; Moss B; Montefiori DC; Robinson HL; Kozlowski PA; Amara RR
J Virol; 2014 Sep; 88(17):9579-89. PubMed ID: 24920805
[TBL] [Abstract][Full Text] [Related]
6. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.
Flamar AL; Xue Y; Zurawski SM; Montes M; King B; Sloan L; Oh S; Banchereau J; Levy Y; Zurawski G
AIDS; 2013 Aug; 27(13):2041-51. PubMed ID: 23615121
[TBL] [Abstract][Full Text] [Related]
7. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS
J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533
[TBL] [Abstract][Full Text] [Related]
8. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.
Melchers M; Matthews K; de Vries RP; Eggink D; van Montfort T; Bontjer I; van de Sandt C; David K; Berkhout B; Moore JP; Sanders RW
Retrovirology; 2011 Jun; 8():48. PubMed ID: 21689404
[TBL] [Abstract][Full Text] [Related]
9. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation.
Fujii S; Liu K; Smith C; Bonito AJ; Steinman RM
J Exp Med; 2004 Jun; 199(12):1607-18. PubMed ID: 15197224
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates.
Flamar AL; Bonnabau H; Zurawski S; Lacabaratz C; Montes M; Richert L; Wiedemann A; Galmin L; Weiss D; Cristillo A; Hudacik L; Salazar A; Peltekian C; Thiebaut R; Zurawski G; Levy Y
PLoS One; 2018; 13(11):e0207794. PubMed ID: 30500852
[TBL] [Abstract][Full Text] [Related]
11. Engaging the CD40-CD40L pathway augments T-helper cell responses and improves control of Mycobacterium tuberculosis infection.
Sia JK; Bizzell E; Madan-Lala R; Rengarajan J
PLoS Pathog; 2017 Aug; 13(8):e1006530. PubMed ID: 28767735
[TBL] [Abstract][Full Text] [Related]
12. CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help.
Hernandez MG; Shen L; Rock KL
J Immunol; 2007 Mar; 178(5):2844-52. PubMed ID: 17312128
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
Gupta S; Termini JM; Raffa FN; Williams CA; Kornbluth RS; Stone GW
J Virol; 2014 Feb; 88(3):1492-501. PubMed ID: 24227853
[TBL] [Abstract][Full Text] [Related]
14. CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells.
Franco D; Liu W; Gardiner DF; Hahn BH; Ho DD
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):393-400. PubMed ID: 21239998
[TBL] [Abstract][Full Text] [Related]
15. Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.
Thompson EA; Liang F; Lindgren G; Sandgren KJ; Quinn KM; Darrah PA; Koup RA; Seder RA; Kedl RM; Loré K
J Immunol; 2015 Aug; 195(3):1015-24. PubMed ID: 26123354
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
Kelleher M; Beverley PC
J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
[TBL] [Abstract][Full Text] [Related]
17. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
[TBL] [Abstract][Full Text] [Related]
18. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
20. CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L.
Price JD; Beauchamp NM; Rahir G; Zhao Y; Rieger CC; Lau-Kilby AW; Tarbell KV
J Leukoc Biol; 2014 Feb; 95(2):325-36. PubMed ID: 24082013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
